The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors

Inés Reynoso-Moreno1,2, Andrea Chicca1, Mario E. Flores-Soto3, Juan M. Viveros-Paredes2* and Jürg Gertsch1*

1 Institute of Biochemistry and Molecular Medicine, National Centre of Competence in Research TransCure, University of Bern, Bern, Switzerland, 2 Laboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Mexico, 3 Laboratorio de Neurobiología Celular y Molecular, División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico

Different anandamide (AEA) transport inhibitors show antinociceptive and anti-inflammatory effects in vivo, but due to their concomitant inhibition of fatty acid amide hydrolase (FAAH) and overall poor bioavailability, they cannot be used unequivocally to study the particular role of endocannabinoid (EC) transport in pathophysiological conditions in vivo. Here, the potent and selective endocannabinoid reuptake inhibitor WOBE437, which inhibits AEA and 2-arachidonoylglycerol (2-AG) transport, was tested for its oral bioavailability to the brain. WOBE437 is assumed to locally increase EC levels in tissues in which facilitated EC reuptake intermediates subsequent hydrolysis. Given the marked polypharmacology of ECs, we hypothesized to see differential effects on distinct EC receptors in animal models of acute and chronic pain/inflammation. In C57BL6/J male mice, WOBE437 was orally bioavailable with an estimated t\textsubscript{max} value of ≤20 min in plasma (C\textsubscript{max} ∼ 2000 pmol/mL after 50 mg/kg, p.o.) and brain (C\textsubscript{max} ∼ 500 pmol/g after 50 mg/kg, p.o.). WOBE437 was cleared from the brain after approximately 180 min. In addition, in BALB/c male mice, acute oral administration of WOBE437 (50 mg/kg) exhibited similar brain concentrations after 60 min and inhibited analgesia in the hot plate test in a cannabinoid CB1 receptor-dependent manner, without inducing catalepsy or affecting locomotion. WOBE437 significantly elevated AEA in the somatosensory cortex, while showing dose-dependent biphasic effects on 2-AG levels in plasma but no significant changes in N-acylethanolamines other than AEA in any of the tissues. In order to explore the presumed polypharmacology mediated via elevated EC levels, we tested this EC reuptake inhibitor in complete Freund's adjuvant induced monoarthritis in BALB/c mice as a model of chronic inflammation. Repetitive doses of WOBE437 (10 mg/kg, i.p.) attenuated allodynia and edema via cannabinoid CB2, CB1, and PPAR\textgamma receptors. The allodynia inhibition of WOBE437 treatment for
INTRODUCTION

The endocannabinoid system (ECS) is an endogenous pan-organ lipid signaling network that modulates numerous biological processes, including neurotransmission, metabolism and immune function (Maccarrone et al., 2015; Iannotti et al., 2016; Ligresti et al., 2016). The major endogenous agonists (i.e., endocannabinoids, ECs) for cannabinoid receptors CB1 and CB2 are the arachidonic acid (AA)-derived lipids 2-arachidonoylglycerol (2-AG) and N-arachidonoylthanolamine (anandamide, AEA). However, these lipids also exert polypharmacological (i.e., pleiotropic) effects via additional proteins, including ion channels like transient receptor potential cation channel subfamily V member 1 (TRPV1) and peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor implicated in inflammatory processes (Di Marzo and De Petrocellis, 2012; Pertwee, 2015; Pistis and O’Sullivan, 2017; Villapol, 2018). Altered EC signaling in the brain has been associated with nociception (Piomelli and Sasso, 2014), learning and memory (Mechoulam and Parker, 2011), anxiety (Lisboa et al., 2017), and others. Overall, the ECS is involved in chronic inflammatory processes and related pain disorders (Lynch, 2016; Barrie and Manolios, 2017; Chiurchiù et al., 2018).

The indirect modulation of EC levels is an attractive therapeutic strategy as it may lead to fewer adverse effects than the direct activation of CB1 receptors in terms of neurotransmission, metabolism and immunomodulation (Di Marzo et al., 2004). In addition to directly targeting EC receptors, indirect cannabimimetics, e.g., inhibitors of the EC degrading enzymes fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), are promising agents for the treatment of certain types of diseases, including inflammatory pain (Chicca et al., 2016). FAAH and MAGL inhibitors such as URB597 (Kathuria et al., 2003) and JZL184 (Long et al., 2009a), respectively, have been instrumental to elucidate the role of AEA and 2-AG in animal models of anxiety and depression (Busquets-Garcia et al., 2011; Bedse et al., 2014; Rubino et al., 2015; Zhang et al., 2015), but also inflammatory diseases and nociception (Trang, 2007; Woodhams et al., 2012, 2017).

Although AEA and 2-AG have different intracellular fates, they may share a common mechanism of membrane trafficking (i.e., facilitated cellular uptake) that is selective for ECs over arachidonate and other N-acylthanolamines (NAEs) (Fegley et al., 2004; Chicca et al., 2012; Nicolussi and Gertsch, 2015). While suitable inhibitors for in vivo research are available for most targets within the ECS (Blankman and Cravatt, 2013), the existing AEA uptake inhibitors lack potency and show poor selectivity over the other components of the ECS, in particular FAAH (Fowler, 2013; Nicolussi and Gertsch, 2015). This is potentially problematic for the interpretation of data obtained with such inhibitors in behavioral paradigms. Conversely, the novel EC transport inhibitor WOBE437 has been shown to selectively block EC cellular reuptake at low nanomolar concentrations in different cellular system in vitro and in vivo, without targeting CB receptors, FAAH, MAGL or fatty acid binding proteins (Chicca et al., 2017). Moreover, WOBE437 is currently the only EC transport inhibitor shown to penetrate the brain at bioactive concentrations (Chicca et al., 2017). Although its molecular mechanism of action remains unknown, evidence has been provided that it primarily acts via elevating EC levels in tissues where EC facilitated cellular reuptake plays a role, e.g., in the CNS or in immune cells (Chicca et al., 2017).

The majority of AEA transport inhibitors currently used exert a range of potential therapeutic effects in animal models (Ligresti et al., 2006; Khasabova et al., 2013; Murillo-Rodriguez et al., 2013; Batista et al., 2014). However, AEA uptake inhibitors like OMDM-2 (Ortar et al., 2003), UCM707 (López-Rodriguez et al., 2001), and AM404 (Beltramo et al., 1997) are poorly selective over FAAH and have not been tested for their oral bioavailability, which it is presumed to be low in animal experiments because some of these inhibitors are degraded by FAAH (Fegley et al., 2004; Chicca et al., 2017). The natural EC reuptake inhibitor guineensine (Nicolussi et al., 2014), despite being inactive at FAAH, has recently been shown to exert potent antiinflammatory effects in vivo but it also targets different CNS receptors in vitro which might explain its CB1 receptor-independent central effects (Reynoso-Moreno et al., 2017). Furthermore, few studies have addressed the uptake inhibition of 2-AG, which is the major endocannabinoid in the brain. 2-AG acts in concert with AEA, as evidenced from differential effects between selective and non-selective FAAH/MAGL inhibitors (Long et al., 2009b; Lau et al., 2014).

The aim of this study was to assess the oral bioavailability of WOBE437 to the brain and obtain data on its tissue distribution over time. We could correlate the oral dose of WOBE437 with both its pharmacological effect in acute pain and overall modulation of lipids related to the ECS. Here, we show that in chronic inflammation, the action of WOBE437 is mediated via different receptors, thus reflecting the pleiotropic action of ECs in complex pathophysiological conditions. These data indicate that the selective inhibition of EC reuptake could be a potential therapeutic strategy for chronic inflammatory conditions in
which different receptors and signaling pathways cooperate in the etiopathology.

**MATERIALS AND METHODS**

**Animals**

Male BALB/c or male C57BL6/J mice (8–10 weeks old; 20–25 g body weight) were either supplied by the Centro de Investigación Biomédica de Occidente or Jackson Laboratory and kept under standard environmental conditions (24 ± 2°C; light–dark cycle of 12:12 h) with food and water *ad libitum*. Mice were handled according to Mexican Federal Regulations for the Care and Use of Laboratory Animals NOM-062-ZOO-1999 (Mexican Ministry of Health) and according to the Swiss federal guidelines, which is in accordance with the Code of Ethics of the Directive 2010/63/EU.

**Oral Bioavailability Experiments**

Male C57BL6/J or male BALB/c mice were orally administered by gavage with 10, 25, 50, or 100 mg/kg of WOBE437 (100 µL; olive oil and ethanol 8:2) using a metal feeding needle (20G, Kent Scientific, United states). The mice were sacrificed by decapitation after gavage administration. Brain, blood, liver, kidney, and spleen were collected for the LC-MS/MS analyses. All tissues were briefly washed with ice cold PBS and immediately snap-frozen and stored at −80°C. Whole brain samples were immediately centrifuged to obtain plasma, which was stored at −80°C.

**Quantification of WOBE437 and Endocannabinoid Levels by LC-MS/MS**

Samples extractions and LC-MS/MS measurements were performed as previously described (Chicca et al., 2017). Briefly, tissues were weighted and transferred in to extraction tubes containing three steel beads and 0.1 M formic acid. Tissues were homogenized and rapidly transferred to glass tubes containing 1.5 mL of ethyl acetate:hexane (9:1) 0.1% formic acid and internal standards (ISs). Samples were centrifuged and the organic phase was recovered. After evaporation, the extracts were reconstituted in 200 µL of ACN:ddH2O (8:2). 10 µL of the solution were injected in the LC-MS/MS system using the same LC and ionization protocols as described (Chicca et al., 2017).

**Microsomal Clearance**

Human or mice microsome clearance experiment were carried out as according to a previously describe protocol (Soethoudt et al., 2017). Briefly, microsome preparation (0.5 mg/mL) plus cofactor NADPH solution was incubated with 1 µM of WOBE437 in 96-well plates at 37°C. After 1, 3, 6, 9, 15, 25, 35, and 45 min, 40 µL of the preparation was transferred and quenched with 3:1 (v/v) acetonitrile containing internal standards. Samples were then cooled and centrifuged before analysis by LC-MS/MS. Log peak area ratios (test compound peak area/internal standard peak area) are plotted against incubation time using a linear fit. The calculated slope is used to determine the intrinsic clearance. Data are obtained from single experiments measured with multiple time-points.

**Hot Plate Test**

Acute pain was evaluated 1 h after gavage administration of WOBE437, at 10, 25, 50, and 100 mg/kg in BALB/c mice. The test was performed using a clean 54–56°C hot plate (Thermo Fisher Scientific, United states) with a Plexiglas cylinder. The latency to show the first nociceptive response (paw lick or foot shake) was measured. In order to evaluate CB1 receptor antagonism, 5 mg/kg of rimonabant (Pharmaserv AG, Switzerland) was injected intraperitoneally (i.p.) (20 µL, in DMSO) 30 min before WOBE437 administration.

**Tetrad Test**

The tetrad test was performed in the following order: rectal temperature, catalepsy, locomotion and analgesia. Rectal temperature was measured before (basal) and 1 h post gavage administration by using a thermocouple probe (Physitemp Instruments Inc., United states) and results were reported as the difference (Δ) between both temperatures. The bar test was used to evaluated catalepsy by placing the mouse in an imposed position with both forelimbs resting on a bar of 4 cm high; the end point of catalepsy was considered when both front limbs were removed or remained over 120 s. Locomotor activity was determined by placing the mouse on a rotarod (Erweka, Germany) at 4 rpm, the latency to fall was measured with a cut-off time of 120 s. Each mouse was previously trained to walk over the rotarod for at least 120 s. Catalepsy and locomotion were measured in three trials. Analgesia was evaluated with the hot plate test, each mouse was placed in a 54–56°C hot plate (Thermo Fisher Scientific, United states) with a Plexiglas cylinder, the latency to first nociceptive response (paw lick or foot shake) was measured.

**Mouse Model of Complete Freund's Adjuvant Induced Monoarthritis**

BALB/c mice were anesthetized with xylazine/ketamine (5 and 10 mg/kg, respectively) and subsequently monoarthritis was induced by intra-articular injection of complete Freund's adjuvant (CFA, 40 µL; Sigma-Aldrich, St. Louis, MO, United states) into the right knee joint. The inflammation was allowed to develop for 14 days prior to pharmacological treatments starting at day 15 for 1 or 3 days, respectively. Mechanical sensitivity (allodynia) and knee diameter (edema) were evaluated 1 h post treatment in the ipsilateral and contralateral knees. Articular sensitivity was evaluated using a digital algometer (Bioseb, United states). The knee withdrawal threshold was determined by applying slow increments of force into the joint until the mice showed a signal of pain (withdrawal reflex or vocalization). A cut-off force of 300 g was considered to avoid damage in the tissue. The measurements were done in triplicates and the average was considered for the statistical analysis. To evaluate the degree of inflammation, knee diameter was measured in both extremities using a digital micrometer (Mitutoyo, United states).
states). WOBE437 was administered at doses of 2.5, 5, or 10 mg/kg, either as single dose or for 3 days treatment. To evaluate the involvement of CB1 and CB2 receptors, TRPV1 and PPARγ, rimonabant (5 mg/kg, CB1 receptor antagonist/inverse agonist), SR144528 (3 mg/kg, CB2 receptor antagonist/inverse agonist; Cayman Chemical, United states), capsazepine (5 mg/kg, TRPV1 antagonist; Tocris Bioscience, United Kingdom) and GW9662 (3 mg/kg, PPARγ antagonist; Tocris Bioscience, United Kingdom) were injected 30 min before WOBE437 administration. Indomethacin (5 mg/kg; Sigma-Aldrich, United Kingdom) were injected 30 min before WOBE437 administration. Indomethacin (5 mg/kg; Sigma-Aldrich, United states) was used as a reference drug (positive control). For all the compounds, dimethylsulfoxide (DMSO) was used as vehicle (20 µL, i.p.).

Open Field Test
Potential motor changes were evaluated in an open field box (40 cm × 40 cm × 30 cm, Plexiglas). The mice were individually placed in the center and allowed to move freely for 5 min. The locomotion activity was recorded with the OpenFieldTest® (Reynoso-Moreno et al., 2017) and traveled distance was evaluated automatically. After every experiment, the box was cleaned with 70% ethanol to remove odors.

Real-Time PCR
To evaluate gene expression of CB receptors and the main enzymes involved in AEA and 2-AG biosynthesis, somatosensory cortex, thalamus and knee articular tissue were recovered after 3 days of treatment with vehicle or WOBE437 in the complete Freund's adjuvant induced monoarthritis model. Total RNA extraction and reverse transcription were carried out with a previously described protocol (Castro-Torres et al., 2015). The kit LightCycler® FastStart DNA MasterPLUS SYBR Green I (Roche, United states) was used for the real-time PCR, according to manufacturer protocol, and the reaction was performed in the LightCycler 2.0 equipment (Roche, United states). The relative gene expression was calculated by using the method known as $2^{(-\Delta \Delta Ct)}$ (Livak and Schmittgen, 2001). $\Delta \Delta Ct$ was calculated using the following formula:

$$\Delta \Delta Ct = (Ct_{TE} - Ct_{HE}) - (Ct_{TC} - Ct_{HC})$$

$Ct_{TE}$: Ct for the tested gene ($Cnr1$, $Cnr2$, Nape-pld, Dagla) in the experimental or control group

$Ct_{HE}$: Ct for the housekeeping gene ($Actb$) in the experimental or control group

$Ct_{TC}$: mean Ct for the tested gene in the control group

$Ct_{HC}$: mean Ct for the housekeeping gene in the control group

Finally $2^{(-\Delta \Delta Ct)}$ was calculated to obtain the fold change of gene expression. Every sample ($n = 6–15$, per group and region) was analyzed in duplicate and the mean value was considered for $\Delta \Delta Ct$ calculation. Beta-actin was used as the housekeeping gene and mean of vehicle group was used as a calibrator. Sequences and size products of the primers for beta actin ($Actb$) cannabinoid CB1 receptor ($Cnr1$), cannabinoid CB2 receptor ($Cnr2$), diacylglycerol lipase alpha (Dagla), N-acylphosphatidylethanolamine specific phospholipase D (Nape-pld) are shown in Table 1.

Statistical Analysis
All data are presented as mean values ± SD and were analyzed by non-parametrical methods using a Kruskal–Wallis test followed by Mann–Whitney U as a post hoc test. A confidence level of $p < 0.05$ was considered statistically significant. Analyses were carried out using the GraphPad Prism software version v5.0 (La Jolla, CA, United States).

RESULTS

The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable
Oral administration of WOBE437 in male C57BL6/J mice showed a complete biodistribution after 20 min, with corresponding brain levels of 24.7 ± 25.3 pmol/g using a dose of 10 mg/kg and 534.5 ± 109.9 pmol/g using a dose of 50 mg/kg (Figure 1A). In plasma, WOBE437 reached 47.3 ± 32.5 and 1731.5 ± 703.4 pmol/mL after oral doses of 10 or 50 mg/kg, respectively (Figure 1A). In order to characterize the tissue distribution of WOBE437 over time, brain and plasma samples were recovered at different time-points (10, 20, 40, 60, 90, and 180 min) after gavage administration of 50 mg/kg. The highest concentration of WOBE437 was found at ≤20 min ($t_{max}$), reaching apparent $C_{max}$ values of 471.7 ± 182.6 pmol/g in brain and 1931 ± 564 pmol/mL in plasma, respectively (Figure 1B). The apparent volume of distribution (Vd) at $C_{max}$ was 80.4 L/kg and at the steady state 609 L/kg, thus large and reflecting lipid solubility and massive tissue penetration/retention. In brain, the value obtained with 50 mg/kg, p.o. is equivalent to an estimated concentration of 399.7 ± 154.7 nM, WOBE437 is cleared from the brain after approximately 180 min. Furthermore, in kidney, liver, and spleen, the $t_{max}$ values of WOBE437 were ≤20 min after administration (Figure 1C). The highest concentration was found in liver with 4720 ± 3273 pmol/g, followed by kidney (2277 ± 916 pmol/g) and spleen (1030 ± 339 pmol/g). Between 20 and 40 min, the hepatic concentration of WOBE437 showed the most significant reduction, dropping by a factor 4 from 4720 to 1080 pmol/g (Figure 1C). In preliminary experiments with human and mouse liver microsomes the clearance of WOBE437 was estimated as 657 and 174 µL/min/kg, respectively (Table 2). These values suggested an estimated maximal bioavailability of 17% in mice and 4% in humans.

Nociceptive Effect After Single Oral Dose of WOBE437
Since WOBE437 has previously shown analgesic effects in different models of acute pain after single i.p. injection (Chicca et al., 2017), we evaluated the pharmacological effects of WOBE437 after oral administration in BALB/c male mice. In a dose-response curve, 50 mg/kg, p.o. of WOBE437 was the minimum dose necessary to significantly increase the pain threshold from 5.8 ± 0.9 s in the vehicle group to 9.4 ± 1.9 s (61.7% increase, Figure 2A). WOBE437 at 100 mg/kg, p.o. marginally further increased the pain threshold to 11.7 ± 2.6 s,
TABLE 1 | Sequences of primers used in the real-time PCR.

| Gen     | Primers     | Product size (bp) | GenBank access number |
|---------|-------------|-------------------|-----------------------|
| Cnr1    | Sense       | 5′-CTT GCA GAT ACC ACC TTC CGT-3′ | 142                   | NM_007726.3          |
|         | Antisense   | 5′-CCC TGA AGG AAG TTA GAG GGA-3′ |                       |                      |
| Cnr2    | Sense       | 5′-GAC AGA AGT GAC CAA CGG CT-3′ | 76                    | X93168.1             |
|         | Antisense   | 5′-GCC ACT GCT CAG GAT CAT GT-3′ |                       |                      |
| Napepld | Sense       | 5′-GCG CCA GAA TTC AGT GCA GA-3′ | 175                   | NM_178728.5          |
|         | Antisense   | 5′-GAG CAC ATT CGG GAT GGA GA-3′ |                       |                      |
| Dagla   | Sense       | 5′-CTC GTC CTG CCA GCT ATC TT-3′ | 157                   | NM_198114.2          |
|         | Antisense   | 5′-TAC AGC TCA GAA GGA TGC CC-3′ |                       |                      |
| Actb    | Sense       | 5′-GGC CAA CGG TGA AAA GAT GA-3′ | 77                    | NM_007393.5          |
|         | Antisense   | 5′-CAG CCT GGA TGG CTA CTT ACA-3′ |                       |                      |

Actb, beta actin; bp, base of pairs; Cnr1, cannabinoid CB1 receptor; Cnr2, cannabinoid CB2 receptor; dagla, diacylglycerol lipase alpha; Napepld, N-acylphosphatidylethanolamine specific phospholipase D (Nape-pld).

**FIGURE 1** | WOBE437 is rapidly biodistributed after oral administration in C57BL6/J male mice. (A) After 20 min post-gavage, WOBE437 was dose-dependently absorbed and reached quantifiable concentrations in brain and plasma. Data show mean values ± SD of 5–10 mice. (B) Time course of WOBE437 concentration in brain and plasma showing an estimated $T_{\text{max}}$ of 10–20 min after administration. Data show mean values ± SD of 5–10 mice. (C) Time course of WOBE437 concentrations in kidney, liver, and spleen, showing the highest concentrations in liver 20 min after administration. p.o., per os. Data show mean values ± SD of 5–10 mice.

thus not significantly more than 50 mg/kg, with an estimated effective dose (ED50) value of 42.5 ± 3.9 mg/kg. The analgesic effect of WOBE437 was mediated through the CB1 receptor as the antinociceptive effect was completely abolished after rimonabant pre-treatment (Figures 2B,C). Additionally, the oral administration of 50 mg/kg of WOBE437 was evaluated in the tetrado test (Figure 3). No statistical differences were found in body temperature, catalepsy or motor coordination, but significant antinociception was measured. However, a tendency to induce hypothermia (Figure 3A) and catalepsy (Figure 3B) was observed as the body temperature decreased from +0.1 ± 0.8°C (control) to −0.8 ± 0.8°C (WOBE437 50 mg/kg) and the latency of catalepsy increased from 5.9 ± 5.4 s (control) to 10.5 ± 10.6 s (WOBE437 50 mg/kg). To further characterize the effects of oral administration of WOBE437, brain and plasma samples were collected after the hot plate test to analyze the EC levels. In somatosensory cortex, 50 mg/kg of WOBE437 showed a significant increase in AEA levels (Figure 4B) but no changes in 2-AG (Figure 4A). In total brain, WOBE437 showed a tendency to increase both AEA and 2-AG levels (Figures 4D,E). Interestingly, in plasma we measured a dose-dependent biphasic effect on 2-AG with a significant rise in 2-AG levels after 50 and 100 mg/kg of WOBE437 (Figure 4G). AEA showed a statistically significant but slight reduction in plasma (Figure 4H). The levels of WOBE437 were similar in somatosensory cortex, total brain and plasma (Figures 4C,F,I) and in the same range as in male C57BL6/J mice (Figure 1B), despite BALB/c showing a tendency toward lower plasma levels (not statistically significant). Overall, the oral administration resulted in high variability of WOBE437 tissue concentrations. No changes in the levels of N-acylethanolamines other than AEA were measured in the somatosensory cortex, total brain or plasma (Figure 5).
WOBE437 Indirectly Triggers Polypharmacological Effects in a Model of Chronic Inflammation

Considering our previous data showing the analgesic and antiinflammatory effects of WOBE437 after single i.p. injection (Chicca et al., 2017) and the confirmation of CB1 receptor-dependent antinociception after oral WOBE437 administration (Figure 2), we decided to further evaluate its pharmacological properties and underlying mechanism(s) in a chronic model of inflammatory pain. After the induction of monoarthritis by intra-articular injection of CFA in mice (Figure 6A), a single dose of WOBE437 at 10 mg/kg, i.p., was able to significantly decrease allodynia (Figure 6B). After 3 days treatment, allodynia was reduced by increasing the pain threshold from 69.0 ± 15.7 g in the vehicle group to 136. 3 ± 31.7 g in the group treated with WOBE437 10 mg/kg, i.p., reflecting a reduction of 52% in allodynia as compared to the contralateral knee (197.0 ± 39.6 g) (Figure 6C). Furthermore, the inflammation (edema) was reduced by 58% resulting in a decrease of the knee diameter from 6.5 ± 0.9 mm in the vehicle group to 5.3 ± 0.4 mm in the WOBE437 10 mg/kg group as compared to the contralateral knee (4.5 ± 0.3 mm) (Figure 6D). The doses of 2.5 and 5.0 mg/kg, i.p., did not show any significant changes. The spontaneous motor activity was measured, but without significant observable changes upon WOBE437 treatment. Nevertheless, a noteworthy tendency to improve spontaneous locomotion was noticed in the monoarthritic group treated with WOBE437 2.5 mg/kg (Figure 6E).

In an attempt to better characterize the downstream mechanism(s) involved in the pharmacological effects mediated by WOBE437 in the monoarthritic model, we pre-treated the mice with cannabinoid CB1 receptor, cannabinoid CB2 receptor, PPARγ and TRPV1 antagonists. In the single dose experiment, the antiallodynia effects of WOBE437 (10 mg/kg, i.p.) were clearly mediated by cannabinoid CB2 and TRPV1 receptors because the CB2 receptor antagonist/inverse agonist SR144528 (3 mg/kg, i.p.) and the TRPV1 antagonist capsazepine (5 mg/kg, i.p.) completely prevented the improvement in mechanical sensitivity by WOBE437 (Figure 7A). Conversely, the CB1 antagonist/inverse agonist rimonabant and PPARγ antagonist GW9662 did not block the effect of WOBE437 in this experiment. Interestingly, a clear multi-target mechanism was seen after 3 days treatment with WOBE437 10 mg/kg, i.p., because the antiallodynia and antiinflammatory effects were fully abolished by each of the cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (5 mg/kg, i.p.), the CB2 antagonist SR144528 (3 mg/kg, i.p.) and PPARγ antagonist GW9662 (3 mg/kg, i.p.) (Figures 7B,C). On the other hand, the antiinflammatory effect was only partially prevented with rimonabant and GW9662 (Figure 7C), indicating additive contributions of CB1 and PPARγ receptors, respectively. In the 3 days WOBE437 treatment we could not use the TRPV1 antagonist capsazepine because the mice showed an unexpected hypersensitivity. In the monoarthritic mice, WOBE437 treatment did not lead to any significant change in the expression of the cannabinoid CB1 receptor (Cnr1), the cannabinoid CB2 receptor (Cnr2) or the enzymes involved in EC production, namely diacylglycerol lipase (Dagla) and N-acylphosphatidylethanolamine specific phospholipase D (Nape-pld) (Figure 8), thus excluding broad transcriptional effects on the ECS.

**DISCUSSION**

**WOBE437 Is Orally Bioavailable to the Brain and Exerts Cannabinoid CB1 Receptor-Dependent Antinociceptive Effects**

As outlined by Arrowsmith et al. (2015), chemical probes are powerful tools with increasing impact on biomedical research. However, probes and inhibitors of poor quality or that are used incorrectly generate misleading results. Among the AEA transport inhibitors, this problem is inherent because they do not generally fulfill the criteria of a good chemical probe, such as potency, selectivity and bioavailability. Importantly, none of the AEA/EC transporter inhibitors (UCM707, OMDM-2, AM404, guineensine) has been investigated for general bioavailability, pharmacokinetic parameters or brain penetration by analytical methods (see below). We recently reported the development of WOBE437 as a novel highly potent and selective EC reuptake inhibitor (SERI) which specifically increases/modulates the levels of the two main ECs AEA and 2-AG in vitro and in vivo (Chicca et al., 2017). WOBE437 showed relevant pharmacological effects in different animal models of acute pain, anxiety and endotoxemia, reaching bioactive concentrations in the brain after intraperitoneal injection (Chicca et al., 2017). Here, we assessed the basic oral bioavailability of WOBE437, its distribution to the brain, plasma and peripheral tissues and evaluated its corresponding antinociceptive and cannabimimetic effects. Considering the stress induced by gavage feeding, the hot plate assay was an ideal nociception paradigm as it avoids chronic stress, unlike, e.g., chronic inflammation. Our results showed quantifiable levels of WOBE437 in brain already 10 min after oral gavage, reaching the highest concentration 20 min after administration, with an estimated $t_{\text{max}}$ of ≤20 min in plasma ($C_{\text{max}} \sim 2000$ pmol/mL after 50 mg/kg, p.o.) and brain ($C_{\text{max}} \sim 500$ pmol/g after 50 mg/kg, p.o.). The WOBE437 concentration in brain remained relatively stable between 300 and 400 pmol/g up to 1 h and was still detectable 3 h after administration (18 pmol/g). A control over the bioavailability and basic pharmacokinetics requirements (e.g., reaching bioactive tissue concentrations) are fundamental to understand the pharmacological effects measured in behavioral...
tests. However, the oral bioavailability of the currently used non-selective AEA transport inhibitors remains unknown. We and others have previously shown that AEA uptake inhibitors like UCM707, AM404, and VDM11 are substrates for h/rFAAH or hMAGL, which strongly suggest their metabolic instability, i.e., degradation after systemic administration (Fegley et al., 2004; Vandevoorde and Fowler, 2005; Chicca et al., 2017). Conversely, WOBE437 is not affected by the hydrolytic activity of FAAH and MAGL and is not modified by COX-2 (Chicca et al., 2017). Nevertheless, the present data show that WOBE437 is significantly metabolized by liver microsomes (human and mouse) after 2 h of incubation, resulting in an estimated oral bioavailability of 4% (human) and 17% (mouse). In the hot plate test, WOBE437 exerted significant analgesic effects at the dose of 50 mg/kg upon oral administration, while the fully effective dose was 10 mg/kg upon systemic administration (i.p.) (Chicca et al., 2017). This difference suggests an overall 20% bioavailability compared to the i.p. administration route, in agreement the estimated maximal bioavailability of 17% calculated in mouse liver microsomes. According to these findings, one could assume that 50 mg/kg, p.o. is almost equivalent to 10 mg/kg, i.p. (i.e., a factor 5). However, the brain levels were approximately 10 times lower after p.o. as compared to i.p. Our previous findings showed that 10 mg/kg of WOBE437 i.p. induced a slight but significant effect in the entire tetrad test battery (hypothermia, catalepsy, hypolocomotion, and analgesia) (Chicca et al., 2017).
FIGURE 4 | Changes in endocannabinoid levels 1 h after oral administration of WOBE437 in BALB/c male mice. In somatosensory cortex, WOBE437 did not change (A) 2-AG levels but significantly increased (B) AEA levels with a single 50 mg/kg dose. (C) Concentration of WOBE437 in somatosensory cortex. In total brain homogenate, (D) 2-AG and (E) AEA did not significantly change after oral administration of a single dose of 50 mg/kg of WOBE437. (F) Concentration of WOBE437 in total brain homogenate. (G) 2-AG levels were significantly increase in plasma with a slightly decrease in (H) AEA. (I) Concentration of WOBE437 in plasma. All data show mean values ± SD of at least 7 to 10 mice. Groups were compared using Kruskal–Wallis test followed by Mann–Whitney test. *p < 0.05 vs. vehicle. 2-AG, 2-arachidonoylglycerol; AEA, anadamide; p.o. per os.
Reynoso-Moreno et al. WOBE437: Oral Bioavailability and Polypharmacology

**FIGURE 5** | Levels of N-acylethanolamines 1 h after oral administration of WOBE437 in BALB/c male mice. (A) Palmitoylethanolamide (PEA), (B) oleoylethanolamine (OEA) and (C) linoleoylethanolamide (LEA) levels in somatosensory cortex. (D) PEA, (E) OEA, and (F) LEA levels in total brain homogenate. (G) PEA, (H) OEA, and (I) LEA levels in plasma. All data show mean values ± SD of at least 5 to 10 mice. Groups were compared using Kruskal–Wallis test followed by Mann–Whitney test. *p < 0.05 vs. vehicle. LOQ, limit of quantification; p.o., per os.
Reynoso-Moreno et al. WOBE437: Oral Bioavailability and Polypharmacology

**FIGURE 6** Effect of WOBE437 on allodynia and inflammation after a single dose or 3 days treatment in a mouse model of monoarthritis. (A) Treatment scheme of monoarthritis induced by knee immunization with complete Freund’s adjuvant (CFA) (40 µL, intra-articular) in which the inflammatory process was allowed to develop for 14 days. Intraperitoneal treatments with WOBE437 were carried out on days 15 to 17. (B) Allodynia was evaluated upon single dose treatments in which 10 mg/kg of WOBE437 increased the pain threshold. After 3 days of treatment, 10 mg/kg of WOBE437 improved (C) allodynia and reduced (D) edema. (E) The development of monoarthritis significantly decreased the travel distance in the open field test, but no significant changes were observed after WOBE437 treatment due to high variability. Indomethacin was used as a reference drug. All doses are shown in mg/kg, i.p. Allodynia was evaluated by mechanical sensitivity and edema through knee diameter and both were measured 1 h after pharmacological treatments. All data show mean values ± SD of at least 6 to 15 mice. Groups were compared using Kruskal–Wallis test followed by Mann–Whitney test. *p < 0.05 vs. ipsilateral/vehicle; #p < 0.05 vs. contralateral/healthy; i.p., intraperitoneally.

Therefore, we also tested the effects of 50 mg/kg of WOBE437 p.o. in BALB/c mice. However, statistical significance was only found for analgesia 1 h after oral administration of WOBE437 but only a tendency to induce hypothermia and catalepsy. This can be explained by the lower levels of WOBE437 in the brain.

One hour after oral administration of WOBE437 at the single dose of 50 mg/kg, a significant increase of AEA levels in the somatosensory cortex was measured, with only a tendency to increase AEA in the total brain. These findings point to a brain region-specific increment in the AEA levels, in agreement with the different EC levels across brain regions and changes in a tissue specific manner (González et al., 2002; Bystrowska et al., 2014; Chicca et al., 2017). Moreover, 2-AG concentration showed a tendency to increase in total brain, from 10.8 ± 2.6 nmol/g to 13.9 ± 2.6 nmol/g after 50 mg/kg of WOBE437, without significant changes in somatosensory cortex. This lack of statistical significance in somatosensory cortex might be due to limited involvement of 2-AG in this area under basal conditions, because significant increase in 2-AG levels have been shown after stress or chronic constriction injury in dorsal midbrain and particularly in periaqueductal grey matter (PAG) (Hohmann et al., 2005; Petrosino et al., 2007). On the contrary, the treatment with 25, 50, and 100 mg/kg of WOBE437 induced a significant increase by 40% of 2-AG levels from 16.1 ± 2.9 pmol/mL to 21.4 ± 4.5 pmol/mL (25 mg/kg), 22.6 ± 4.8 pmol/mL (50 mg/kg) and 23.8 ± 5.7 pmol/mL (100 mg/kg) in plasma. On the other hand, the concentration of AEA in plasma was weakly but significantly reduced by 23%, from 2.6 ± 0.2 pmol/mL in the control group to 2.2 ± 0.3 pmol/mL in the group treated with WOBE437 at 50 mg/kg. This slight decrease in AEA levels may not cause biological effects but could rather reflect differential AEA transport kinetics between AEA and 2-AG in a complex tissue environment. We have previously shown that AEA and 2-AG compete for cellular uptake in vitro with different affinities (Chicca et al., 2012). Finally, the effects of WOBE437 on circulating ECs upon i.p. administration exhibited yet a different pattern leading to significant increase of 2-AG levels as compared to vehicle (after 15 min) but without affecting AEA levels (Chicca et al., 2017).

**Selective Inhibition of Endocannabinoid Uptake Through WOBE437 Triggers Polypharmacological Effects in Inflammatory Pain**

To evaluate the preclinical potential of WOBE437, or in general of selective inhibition of the EC reuptake process, chronic inflammatory pain was induced by the intra-articular injection...
of CFA, with the subsequent development of monoarthritis-like conditions. Consecutive treatment for 3 days with 10 mg/kg of WOBE437 significantly attenuated allodynia and edema induced during monoarthritis. The allodynia was already reduced by single injection of 10 mg/kg of WOBE437. In models of CFA-induced persistent inflammatory pain, the antiallodynia effects of cannabinomimetics such as WIN55212-2, AM404, and ajulemic acid, have been previously shown to be mediated either via cannabinoid CB1 receptors or cannabinoid CB2 receptors (Mitchell et al., 2007; Vann et al., 2007; Li et al., 2017). Moreover, both cannabinoid CB1 and CB2 receptors have shown to be involved in the antiallodynic effect of JZL195, a dual inhibitor of AEA and 2-AG degradation (Anderson et al., 2014), suggesting a pleotropic multi-target mechanism associated to the simultaneous increase of both AEA and 2-AG levels (Di Marzo and De Petrocellis, 2012; Pertwee, 2015; Pistis and O’Sullivan, 2017). Given the fact that WOBE437 inhibits the reuptake of both AEA and 2-AG, we
Our data also show the involvement of CB2 receptors in the antinociceptive or antiallodynic effects through TRPV1 activation observed after single administration of WOBE437 reflects the pleiotropic biological actions of both ECs, specifically through the activation of TRPV1 (AEA) and CB2 receptors (2-AG). In the 3 days WOBE437 treatment we could not use the TRPV1 agonist capsazepine because the mice showed an unexpected hypersensitivity, which appeared to be caused by concomitant WOBE437 and capsazepine administration. Our data suggest that the potentiation of EC signaling obtained by blocking cellular EC reuptake, and potentially interfering with AEA trafficking in a bidirectional manner (side infra), leads to alleviation of alldynia by a common potentially synergistic signaling pathway activated by cannabinoid CB2 and CB1 receptors, PPARγ and possibly TRPV1. On the other hand, the antiinflammatory effect seems to be associated to more than one mechanism of action in which activation of CB2 receptors is predominant. Thus, EC signaling through CB1 receptor and PPARγ activation might only partially contribute to the antiinflammatory effect in this mouse model of monoarthritis. Since WOBE437 after 3 days treatment did not influence transcription of CB receptors or the enzymes involved in the generation of ECs we excluded indirect effects on gene expression of the major proteins of the ECS.

A possible common signaling node activated by cannabinoid CB1, CB2, and PPARγ receptors could be at the transcriptional level. In animal models of adjuvant-induced arthritis, osteoarthritis and neuroinflammation, it has been observed that independent activation of CB2 receptor and PPARγ can inhibit the activation of the canonical transcription factor NF-κB (Fakhfouri et al., 2012; Saravanan et al., 2014) and the mitogen-activated protein kinases (MAPKs) (Li et al., 2013; Moens et al., 2013; Ribeiro et al., 2013; Ma et al., 2015). This inhibition attenuates the expression and final release of pro-inflammatory mediators such tumor necrosis factor-α, interleukin 1-β, but also iNOS and COX2 (Fakhfouri et al., 2012; Luo et al., 2014), which are associated with the pain sensitization and the edema formation seen after CFA injection (Khan et al., 2013; Li et al., 2013; Luo et al., 2014). On the other hand, activation of cannabinoid CB1 receptors can also modulate NF-κB and MAPKs pathways via upregulation of the transcriptional activity of PPARγ (Du et al., 2011; Carroll et al., 2012; Fakhfouri et al., 2012; Ignatowska-Jankowska et al., 2014). In addition, ECs have been shown to modulate the activation of PPARγ through three possible mechanisms: (1) direct binding/activation, (2) via metabolites generated after AEA and 2-AG degradation, or (3) via cannabinoid CB1/CB2 receptor-mediated downstream signaling (i.e., MAPKs) (Burstein, 2005; O’Sullivan, 2007; O’Sullivan and Kendall, 2010). Therefore, ECs might modulate the inflammatory stage in monoarthritic mice through the inhibition of NF-κB/MAPKs signaling pathways, as a plausible explanation of the indirect polypharmacological
effects of WOBE437 after 3 days of treatment. Nevertheless, further experiments are necessary to understand the exact molecular mechanism. There are not direct reports about the involvement of PPARγ in the pharmacological effects of MAGL or FAAH inhibitors in vivo. However, in an in vitro model of neuroinflammation, the pharmacological effects of the MAGL inhibitor JZL184 and the FAAH inhibitor URB597 were shown to be mediated by PPARγ in a CB1 receptor-dependent manner (Du et al., 2011). In addition, the antidysonkinetic effects of URB597 in combination with capsazepine were reversed by a non-selective PPAR antagonist, and in the same model a PPARγ selective agonist showed a significant reduction of dyskinesia (Martinez et al., 2015). Conversely, in an acute model of carrageenan-induced inflammatory hyperalgesia, PPARs but not PPARγ was involved in the analgesic effects of URB597 (Jhaveri et al., 2008). These reports might suggest that PPARγ is primarily involved in chronic but not acute inflammatory conditions (Villapol, 2018). Thus, cannabinoid receptors and PPAR may potentially constitute a synergic antiinflammatory signaling network. The pharmacological differences between WOBE437 and FAAH/MAGL inhibitors could involve tissue selectivity, the degree of increment in ECS levels and the differential extracellular EC accumulation leading to increased cannabinoid CB1 and CB2 receptor activation. However, the present data point toward a more complex action of WOBE437 as also the intracellular AEA receptors TRPV1 and PPARγ were involved in the analgesic effects of this EC reuptake inhibitor, accompanied by a weak but significant decrease of AEA in plasma. Therefore, we cannot exclude bidirectional transport effects in vivo as shown previously in vitro (Chicca et al., 2012; Nicolussi and Gertsch, 2015).

CONCLUSION

The novel EC reuptake inhibitor WOBE437 not only exhibits a high potency and selectivity (Chicca et al., 2017) but also matches the bioavailability criteria (in mice) that depict an adequate pharmacological tool compound. By applying WOBE437 in different mouse models of pain and inflammation, we found that the inhibition of EC reuptake triggers differential effects via elevation of ECS in different tissues and distinct pathophysiological/nociceptive contexts. This is in strong agreement with data obtained from the dual inhibition of AEA and 2-AG degradation (Anderson et al., 2014). Moreover, our data obtained with WOBE437 treatment reveal the noteworthy polypharmacology mediated by cannabinoid CB2, CB1, TRPV1, and PPARγ receptors in a mouse monoarthritis pain model. This indicates that this class of ECS modulators has the potential to exert therapeutic effects in chronic inflammatory conditions in which the pleiotropic effects of AEA and 2-AG counteract the pathophysiology. Therefore, SERIs together with non-selective FAAH/MAGL inhibitors are promising indirect cannabimimetics and should be further investigated in preclinical models of chronic inflammatory pain.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of NOM-062-ZOO-1999 and Code of Ethics of the Directive 2010/63/EU. The protocol was approved by the Departamento de Farmacología, Centro Universitario de Ciencias Exactas e Ingenierías.

AUTHOR CONTRIBUTIONS

JV-P and JG designed the project. JV-P, JG, AC, MF-S, and IR-M planned and supervised the research. IR-M and MF-S carried out the experiments. IR-M obtained and processed the data. IR-M and JG drafted the manuscript. IR-M, JG, AC, and JV-P contributed to the writing of the manuscript. All authors saw the data, discussed the interpretation of experiments, and approved the final version.

FUNDING

The study was funded by Consejo Nacional de Ciencia y Tecnología (CONACYT) Mexico and the NCCR TransCure (SNSF) Switzerland. We also acknowledge F. Hoffmann-La Roche AG, Switzerland for a grant within the EIN program.

ACKNOWLEDGMENTS

We would like to acknowledge Vanessa Petrucci and Sandra Glasmacher for her support related to LC-MS/MS. We also acknowledge F. Hoffmann-La Roche AG, Switzerland for measuring the liver microsome stability. IR-M thanks Dr. Carlos Beas Zarate for his support and guidance.

REFERENCES

Anderson, W. B., Gould, M. J., Torres, R. D., Mitchell, V. A., and Vaughan, C. W. (2014). Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model. *Neuropharmacology* 81, 224–230. doi: 10.1016/j.neuropharm.2013.12.018

Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., et al. (2015). The promise and peril of chemical probes. *Nat. Chem. Biol.* 11, 536–541. doi: 10.1038/nchembio.1867

Barrie, N., and Manolios, N. (2017). The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. *Eur. J. Rheumatol.* 4, 210–218. doi: 10.5152/eurjrheum.2017.17025

Batista, L. A., Gobira, P. H., Viana, T. G., Aguiar, D. C., and Moreira, F. A. (2014). Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. *Behav. Pharmacol.* 25, 425–433.

Bedse, G., Colangeli, R., Lavecchia, A. M., Romano, A., Altieri, F., Cifani, C., et al. (2014). Role of the basolateral amygdala in mediating the effects of the fatty acid amide hydrolase inhibitor URB597 on HPA axis response to stress. *Eur. Neuropsychopharmacol.* 24, 1511–1523. doi: 10.1016/j.euroneuro.2014.07.005

Beltramelli, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., and Piomelli, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. *Science* 277, 1094–1097.
Blankman, J. L., and Cravatt, B. F. (2013). Chemical probes of endocannabinoid metabolism. *Pharmacol. Rev.* 65, 849–871. doi: 10.1124/pr.112.006387

Burstein, S. (2005). PPAR-γ: a nuclear receptor with affinity for cannabinoids. *Life Sci.* 77, 1674–1684. doi: 10.1016/J.LFS.2005.05.039

Busquets-Garcia, A., Puighermanal, E., Pastor, A., De La Torre, R., Maldonado, R., and Ozaita, A. (2011). Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. *Biol. Psychiatry* 70, 479–486. doi: 10.1016/j.biopsych.2011.04.022

Bystrowska, B., Smaga, I., Frankowska, M., and Filip, M. (2014). Changes in endocannabinoid and N-acyl ethanolamine levels in rat brain structures following cocaine self-administration and extinction training. *Prog. Neuro Psychopharmacol. Biol. Psychiatry* 50, 1–10. doi: 10.1016/j.pnpbp.2013.12.002

Carroll, C. B., Zeissler, M.-L., Hanemann, C. O., and Zajicek, J. P. (2012). WIN55212-2 attenuates amyloid-beta-induced neuroinflammation through inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol mediated via PPAR-γ. *Br. J. Pharmacol.* 163, 1533–1549. doi: 10.1111/j.1476-5381.2011.01444.x

Castro-Torres, R. D., Chaparro-Huerta, V., Flores-Soto, M. E., Jave-Suárez, L., Camins, A., Armendáriz-Borunda, J., et al. (2015). Pirfenidone attenuates microglial reactivity and reduces inductive nitric oxide synthase mRNA expression following kainic acid-mediated excitotoxicity in pseusebasal rat hippocampus. *J. Mol. Neurosci.* 56, 245–254. doi: 10.1007/s12031-015-0505-9

Chicca, A., Arena, C., and Manera, C. (2016). Beyond the direct activation of cannabinoid receptors: new strategies to modulate the endocannabinoid system in CNS-Related diseases. *Recent Pat. CNS Drug Discov.* 11, 160, 82–100. doi: 10.3233/RPC-160410

Di Marzo, V., Bifulco, M., and De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. *Proc. Natl. Acad. Sci. U.S.A.* 101, 1476-15381.2011.01444.x

Fakhfouri, G., Ahmadiani, A., Rahimian, R., Grolla, A. A., Moradi, F., and Haeri, A. (2012). Neuroendocannabinoid signaling in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training. *Br. J. Pharmacol.* 163, 1533–1549. doi: 10.1111/j.1476-5381.2011.01444.x

Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fedegy, D., Mangieri, R., et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. *Nature* 435, 1108–1112. doi: 10.1038/nature03658

Horvath, G., Kekesi, G., Nagy, E., and Benedek, G. (2008). The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. *Pain* 134, 277–280. doi: 10.1016/j.pain.2007.04.032

Iannotti, F. A., Di Marzo, V., and Petrosino, S. (2016). Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. *Prog. Lipid Res.* 62, 107–128. doi: 10.1016/j.plipres.2016.02.002

Ignotowska-Jankowska, B. M., Ghosh, S., Crowe, M. S., Kinsey, S. G., Niphakis, M. J., Abdullah, R. A., et al. (2014). In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. *Br. J. Pharmacol.* 171, 1392–1407. doi: 10.1111/bph.12298

Jhuveri, M. D., Richardson, D., Robinson, I., Garle, M. J., Patel, A., Sun, Y., et al. (2008). Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. *Neuropharmacology* 55, 85–93. doi: 10.1016/j.neuropharm.2008.04.018

Kathuria, S., Gaetani, S., Fegley, D., Valinó, F., Duranti, A., Tontini, A., et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. *Nat. Med.* 9, 76–81. doi: 10.1038/nm0303

Khase, S., Shehzad, O., Chun, J., and Kim, Y. S. (2013). Mechanism underlying anti-hyperalgesic and anti-allodynic properties of anabulin in both acute and chronic inflammatory pain models in mice through inhibition of NF-κB, MAPKs and CREB signaling cascades. *Eur. J. Pharmacol.* 718, 448–458. doi: 10.1016/j.ejphar.2013.07.039

Khasabova, I. A., Holman, M., Morse, T., Burlakova, N., Coicou, L., Harding-Rose, C., et al. (2013). Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. *Neurobiol. Dis.* 58, 19–28. doi: 10.1016/j.nbd.2013.05.018

Klauke, A.-L., Raza, I., Pradier, B., Markert, A., Zimmer, A. M., Gertch, J., et al. (2014). The cannabinoid CB2 receptor-selective phytoannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. *Eur. Neuropsychopharmacol.* 24, 608–620. doi: 10.1016/j.europharm.2014.10.008

Lau, B. K., Drew, G. M., Mitchell, V. A., and Vaughan, C. W. (2014). Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey. *Br. J. Pharmacol.* 171, 5225–5236. doi: 10.1111/bph.12839

Li, M.-H., Suchland, K. L., and Ingram, S. L. (2017). Compensatory activation of cannabinoid CB2 receptor inhibition of GABA release in the rostral ventromedial medulla mediates anti-inflammatory pain. *J. Neurosci.* 37, 626–636. doi: 10.1523/JNEUROSCI.1310-16.2016

Li, Y. Y., Yuece, B., Cao, H. M., Lin, H. X., Lv, S., Chen, J. C., et al. (2013). Inhibition of p38/MK2 signaling pathway improves the antiinflammatory effect of WIN55 on mouse experimental colitis. *Lab. Invest.* 93, 322–333. doi: 10.1038/labinvest.2012.177

Liao, H.-T., Lee, H.-J., Ho, Y.-C., and Chiou, L.-C. (2011). Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptor-mediated endocannabinoid retrograde disinhibition. *Br. J. Pharmacol.* 163, 330–345. doi: 10.1111/j.1476-5381.2011.01214.x

Ligresti, A., Cascio, M. G., Pucea, G., Kulsegrazam, S., Beletskaya, I., De Petrocellis, L., et al. (2006). New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. *Br. J. Pharmacol.* 147, 83–91. doi: 10.1038/bj.2006.418

Ligresti, A., De Petrocellis, L., and Di Marzo, V. (2016). From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. *Physiol. Rev.* 96, 1593–1659. doi: 10.1152/physrev.00002.2016

Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. *Methods* 25, 402–408. doi: 10.1006/meth.2001.1262
Nicolussi, S., Viveros-Paredes, J. M., Gachet, M. S., Rau, M., Flores-Soto, M. E., Blunder, M., et al. (2014). Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabinimetic behavioral effects in BALB/c mice. Pharmacol. Res. 80, 52–65. doi: 10.1016/j.phrs.2013.12.010

Ortar, G., Ligresti, A., De Petrocellis, L., Morera, E., and Di Marzo, V. (2003). Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65, 1473–1481.

O’Sullivan, S. E. (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 152, 576–582. doi: 10.1038/jb.2007.423

O’Sullivan, S. E., and Kendall, D. A. (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215, 611–616. doi: 10.1016/j.imbio.2009.09.007

Pertwee, R. G. (2015). Endocannabinoids and their pharmacological actions. Handb. Exp. Pharmacol. 231, 1–37. doi: 10.1007/978-3-319-20825-1_1

Petrozino, S., Palazzo, E., de Novellis, V., Bisogno, T., Rossi, F., Maione, S., et al. (2007). Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52, 415–422. doi: 10.1016/j.neuropharm.2006.08.011

Piomelli, D., and Sasso, O. (2014). Peripheral gating of pain signals by endogenous lipid mediators. Nat. Neurosci. 17, 164–174. doi: 10.1038/nrn3612

Pistis, M., and O’Sullivan, S. E. (2017). The role of nuclear hormone receptors in cannabinoid function. Adv. Pharmacol. 80, 291–328. doi: 10.1016/bs.appc.2017.03.008

Racz, I., Nadal, X., Alferink, J., Baños, J. E., Rehnelt, J., Martin, M., et al. (2008). Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J. Neurosci. 28, 12125–12135. doi: 10.1523/JNEUROSCI.3400–08.2008

Reynoso-Moreno, I., Najar-Guerrero, L., Escareño, N., Flores-Soto, M. E., Gertsch, J., and Viveros-Paredes, J. M. (2017). An endocannabinoid uptake inhibitor from black pepper exerts pronounced antiinflammatory effects in mice. J. Agric. Food Chem. 65, 9435–9442. doi: 10.1021/acs.jafc.7b02979

Ribiero, R., Wen, J., Li, S., and Zhang, Y. (2013). Involvement of ERK1/2, p38α and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat. 10, 1–14. doi: 10.1016/j.prostaglandins.2012.06.011

Rubino, T., Zamberletti, E., and Parolaro, D. (2015). Endocannabinoids and mental disorders. Handb. Exp. Pharmacol. 231, 261–283. doi: 10.1007/978–319–26825–1_9

Saravanan, S., Hairul Islam, I. V, Prakash Babu, N., Pandikumar, P., Thirunagaranam, K., Chellappandan, M., et al. (2014). Swertiamarin attenuates inflammation mediators via modulating NF-κB/I κB and JAK2/STAT3 transcription factors in adjuvant induced arthritis. Eur. J. Pharm. Sci. 56, 70–86. doi: 10.1016/j.ejps.2014.02.005

Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., et al. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 128, 1111–1117. doi: 10.1017/s0007119200051735

Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., De Petrocellis, L., et al. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signaling and off-target activity. Nat. Commun. 8:13958. doi: 10.1038/ncomms13958

Starowicz, K., Maione, S., Cristino, L., Palazzo, E., Marabese, I., Rossi, F., et al. (2007a). Tonic endovaniloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci. 27, 13739–13749. doi: 10.1523/JNEUROSCI.3258–07.2007

Starowicz, K., Makuch, W., Osikowicz, M., Piscitelli, F., Petrozino, S., Di Marzo, V., et al. (2012). Spinal anandamide produces analgesia in neuropathic rats: possible CB1- and TRPV1-mediated mechanisms. Neuropharmacology 62, 1746–1755. doi: 10.1016/j.neuropharm.2011.11.021

Starowicz, K., Nagam, S., and Di Marzo, V. (2007b). Biochemistry and pharmacology of endovaniloids. Pharmacol. Ther. 114, 13–33. doi: 10.1016/j.pharmthera.2007.01.005

Szabo, A., Helyes, Z., Sandor, K., Bite, A., Pintér, É., Németh, J., et al. (2005). Role of transient receptor potential potential vanilloid 1 receptors in adjuvant-induced chronic arthritis: in vivo study using gene-deficient mice. J. Pharmacol. Exp. Ther. 314, 111–119. doi: 10.1124/jpet.104.082487

Trang, T. (2007). Inhibition of fatty acid amide hydrolase: a potential treatment for neuropathic pain. J. Neurosci. 27, 3364–3365. doi: 10.1523/JNEUROSCI.0583–07.2007

Vandervoorde, S., and Fowler, C. J. (2005). Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as a FAAH substrate. Br. J. Pharmacol. 145, 885–893. doi: 10.1038/sj.bjp.0706233
Vann, R. E., Cook, C. D., Martin, B. R., Wiley, J. L., Phillips, M., Huffman, J. W., et al. (2007). Cannabimimetic properties of ajulemic acid. *J. Pharmacol. Exp. Ther.* 320, 678–686. doi: 10.1124/jpet.106.111625

Villapol, S. (2018). Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. *Cell. Mol. Neurobiol.* 38, 121–132. doi: 10.1007/s10571-017-0554-5

Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., and Neugebauer, V. (2017). The cannabinoid system and pain. *Neuropharmacology* 124, 105–120. doi: 10.1016/j.neuropharm.2017.06.015

Woodhams, S. G., Wong, A., Barrett, D. A., Bennett, A. J., Chapman, V., and Alexander, S. P. H. (2012). Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. *Br. J. Pharmacol.* 167, 1609–1619. doi: 10.1111/j.1476-5381.2012.02179.x

Zhang, Z., Wang, W., Zhong, P., Liu, S. J., Long, J. Z., Zhao, L., et al. (2015). Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity. *Hippocampus* 25, 16–26. doi: 10.1002/hipo.22344

Conflict of Interest Statement: JG has been mentioned as an inventor in the patent WO2010136221A1.

The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Reynoso-Moreno, Chicca, Flores-Soto, Viveros-Paredes and Gertsch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.